Membranoproliferative Glomerulonephritis following the Oxford AstraZeneca COVID-19 Vaccine by Kawtar Hassani, Majdouline Errihani, Mohamed Houssein Mahamoud, Driss ElKabbaj

Get full text

Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in Vietnamese healthcare workers by Van Vinh Chau, N, Nguyet, LA, Truong, NT, Toan, LM, Dung, NT, Hung, LM, Nhan, MT, Huy Man, DN, Ngoc, NM, Thao, HP, Hoang Tu, TN, Mai, HK, Hung, DT, Han Ny, NT, Thanh, LK, Anh, NT, Thu Hong, NT, Truc Nhu, LN, Yen, LM, Choisy, M, Thanh, TT, Thwaites, G, Van Tan, L

“…At month 3, neutralizing antibodies decreased and 94.7% (89 of 94) of the study participants remained seropositive. The Oxford-AstraZeneca COVID-19 vaccine is immunogenic in Vietnamese health-care workers. …”

Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in Vietnamese health-care workers by Chau, NVV, Nguyet, LA, Truong, NT, Toan, LM, Dung, NT, Hung, LM, Nhan, MT, Man, DNH, Ngoc, NM, Thao, HP, Tu, TNH, Mai, HK, Hung, DT, Ny, NTH, Thanh, LK, Anh, NT, Hong, NTT, Nhu, LNT, Yen, LM, Choisy, M, Thanh, TT, Thwaites, G, Tan, LV

“…At month 3, neutralizing antibodies decreased and 94.7% (89 of 94) of the study participants remained seropositive. The Oxford-AstraZeneca COVID-19 vaccine is immunogenic in Vietnamese health-care workers. …”

Adverse effects of Oxford-AstraZeneca COVID-19 vaccine among Egyptian healthcare workers by Mai Al Kaffas, Amal Aboelnour, Manal H.Abuelela

Get full text

Rhabdomyolysis following Oxford/AstraZeneca COVID-19 vaccination; two case reports from Iran by Marzieh Hashemi, Ghazaleh Sajadi, Samaneh Pourajam

“…The present study intended to report two cases of rhabdomyolysis due to vaccination with Oxford/AstraZeneca COVID-19 vaccines. The patients were two men aged 70 and 75 years old who presented to a healthcare facility with weakness, myalgia, nausea, and vomiting for about ten days after receiving their first dose of the Oxford/AstraZeneca COVID-19 vaccine. …”
Get full text

Systemic drug-related intertriginous and flexural exanthema-like eruption after Oxford-AstraZeneca COVID-19 vaccine by Danilo Di Bona, Andrea Miniello, Eustachio Nettis

Get full text

Bilateral acute macular neuroretinopathy in a young woman after the first dose of Oxford–AstraZeneca COVID-19 vaccine by Pierre-Henry Gabrielle, Florian Baudin, Ines Ben Ghezala, Cyril Meillon, Alain Marie Bron, Louis Arnould, Catherine Creuzot-Garcher

“…These symptoms occurred 24 h after receiving the first Oxford-AstraZeneca COVID-19 vaccination dose. The ophthalmologic signs were preceded a few hours earlier by fever and flu-like symptoms. …”
Get full text

A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report by Samuel B. M. Williams, Stephen D. J. Holwill, Rhian L. Clissold, Coralie Bingham

“…Conclusions To our knowledge, this was the first described case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine, although a number of cases have emerged more recently. …”
Get full text

Low credibility URL sharing on Twitter during reporting linking rare blood clots with the Oxford/AstraZeneca COVID-19 vaccine. by Ali Hobbs, Aisha Aldosery, Patty Kostkova

Get full text

ANCA-associated vasculitis following Oxford-AstraZeneca COVID-19 vaccine in Brazil: Is there a causal relationship? A case report by Welder Zamoner, Julia Baldon Scardini, Bruna Jordana De Dio, Amanda de Melo Marques, Vanessa dos Santos Silva, Aline Lutz Garcia, Daniela Cristina dos Santos, Rosa Marlene Viero

“…This article presents a case of rapidly progressive glomerulonephritis following the Oxford-AstraZeneca COVID-19 vaccine in a female patient 58 years old. …”
Get full text

Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups by Whitaker, HJ, Tsang, RSM, Byford, R, Andrews, NJ, Sherlock, J, Sebastian Pillai, P, Williams, J, Button, E, Campbell, H, Sinnathamby, M, Victor, W, Anand, S, Linley, E, Hewson, J, DArchangelo, S, Otter, AD, Ellis, J, Hobbs, RFD, Howsam, G, Zambon, M, Ramsay, M, Brown, KE, de Lusignan, S, Amirthalingam, G, Lopez Bernal, J

The knowledge, attitudes, and perceptions toward the Oxford AstraZeneca COVID-19 vaccine amongst Primary Health care workers in North-Central Trinidad by Raveed Khan, Rachel Albert, Leann Awe, Renee De Four, Tichad Francois, Tahirah Hinds, Avery Kellman, Kelsey Maharaj, Renea Mahon, Chanel Pierre, Alana Ramai, Rameez Baksh

Get full text

Prospective Evaluation of Side-Effects Following the First Dose of Oxford/AstraZeneca COVID-19 Vaccine among Healthcare Workers in Saudi Arabia by Majid A. Darraj, Hesham M. Al-Mekhlafi

“…Conclusions: Findings of the present study support the safety of the Oxford/AstraZeneca COVID-19 vaccine among HCWs in Saudi Arabia. …”
Get full text

Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study. by Majid Eterafi, Nasrin Fouladi, Majid Golizadeh, Hamidreza Shaker, Somaieh Matin, Elham Safarzadeh

Get full text

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database by Mansour Tobaiqy, Katie MacLure, Hajer Elkout, Derek Stewart

“…A retrospective descriptive analysis was conducted of spontaneous reports for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines submitted to the EudraVigilance database in the period from 17 February to 14 June 2021. …”
Get full text

Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study by Elias Ali Yesuf, Abanoub Riad, Abanoub Riad, Ahmad Sofi-Mahmudi, Ahmad Sofi-Mahmudi, Morankar Sudhakar, Addisalem Mekonnen, Selamawit Endalkachew, Feyissa Mama, Semira Muhidin, Bethelhem Ayele, Mohammed Yahya, Abduselam Usman, Jemal Abafita, Miloslav Klugar, Miloslav Klugar

“…Healthcare workers were the priority population that received the Oxford AstraZeneca COVID-19 vaccine. However, there was no nationwide study on the safety of the vaccine in Ethiopia. …”
Get full text

Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum by Amit Kaura, Adam Trickey, Anoop S V Shah, Umberto Benedetto, Ben Glampson, Abdulrahim Mulla, Luca Mercuri, Sanjay Gautama, Ceire E Costelloe, Ian Goodman, Julian Redhead, Kavitha Saravanakumar, Erik Mayer, Jamil Mayet

Get full text

COVID-19 outbreak response at a nursing hospital in South Korea in the post-vaccination era, including an estimation of the effectiveness of the first shot of the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1-S) by Chanhee Kim, Geon Kang, Sun Gu Kang, Heeyoung Lee

Get full text

A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran by Shahin Soltani, Behzad Karami Matin, Mohammad Mehdi Gouya, Sayed Mohsen Zahraei, Ghobad Moradi, Omid Chehri, Moslem Soofi, Mehdi Moradinazar, Fatemeh Khosravi Shadmani, Mahsa Kalantari, Hamidreza Khajeha, Mohammad Hassan Emamian, Farid Najafi

Get full text

Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative S... by Yazed AlRuthia, Haya F. Al-Salloum, Omar A. Almohammed, Amani S. Alqahtani, Hana A. Al-Abdulkarim, Yousef M. Alsofayan, Sami S. Almudarra, Sara H. AlQahtani, Abdullah Almutlaq, Khaled Alabdulkareem, Bander Balkhi, Hamoud T. Almutairi, Abdullah S. Alanazi, Yousif A. Asiri

Subjects: Get full text